Unyango lwe-Immunotherapy njengoNyango lweNqanaba lesiBini lweCancer Cancer engeyiyo encinci

Umxholo

• I-Immunotherapy: Isebenza njani
• I-inhibitors yokujonga indawo yeNSCLC
• Ungayifumana nini i-immunotherapy?
• Uyifumana njani i-immunotherapy?
• Basebenza kakuhle kangakanani?
• Zithini iziphumo ebezingalindelekanga?
• Yise kude

Emva kokuba ufunyaniswe unesifo somhlaza wamaphaphu ongekho mncinci (NSCLC), ugqirha wakho uya kuhamba nawe ngonyango lwakho. Ukuba unomdlavuza kwinqanaba lokuqala, utyando luhlala lukhetho lokuqala. Ukuba umhlaza wakho uhambele phambili, ugqirha wakho uya kuwunyanga ngotyando, ngekhemotherapy, ngemitha, okanye ngokudityaniswa kwezi zintathu.

Unyango lwe-Immunotherapy lunokuba lunyango lwesibini lwe-NSCL. Oku kuthetha ukuba ungangumgqatswa we-immunotherapy ukuba ichiza lokuqala ozamayo alisebenzi okanye liyeke ukusebenza.

Ngamanye amaxesha oogqirha basebenzisa i-immunotherapy njengonyango lokuqala kunye namanye amachiza kumagqabi omhlaza asasazeke kuwo wonke umzimba.

I-Immunotherapy: Isebenza njani

I-Immunotherapy isebenza ngokukhuthaza amajoni akho omzimba ukuba afumane kwaye abulale iiseli zomhlaza. Amachiza e-immunotherapy asetyenziselwa ukunyanga i-NSCLC kuthiwa yi-checkpoint inhibitors.

Amajoni akho omzimba anamaseli abulalayo abizwa ngokuba zii-T seli, azingela umhlaza kunye nezinye iiseli eziyingozi zamanye amazwe kwaye azitshabalalise. Iindawo zokutshekisha ziiproteni kumphezulu weeseli. Benza iiseli ze-T zazi ukuba iseli inobuhlobo okanye iyingozi. Iindawo zokujonga zikhusela iiseli ezisempilweni ngokuthintela amajoni akho omzimba ekuhlaseleni ngokuchasene nawo.

Iiseli zomhlaza ngamanye amaxesha zinokusebenzisa ezi ndawo zokujonga ukufihla kumajoni omzimba. I-Checkpoint inhibitors zivimba iiproteni zokujonga ukuze iiseli ze-T zikwazi ukubona iiseli zomhlaza kwaye zibatshabalalise. Ngokusisiseko, la machiza asebenza ngokususa iziqhoboshi kwimpendulo yomzimba yokuzikhusela ngokuchasene nomhlaza.

I-inhibitors yokujonga indawo yeNSCLC

Amachiza amane e-immunotherapy anyanga i-NSCLC:

• INivolumab (Opdivo) kunye nepembrolizumab (Keytruda)
  vimba iprotein ebizwa ngokuba yi-PD-1 kumphezulu weeseli T. I-PD-1 ithintela iiseli ze-T
  ekuhlaselweni ngumhlaza. Ukuthintela iPD-1 kuvumela amajoni omzimba ukuba azingele
  kunye nokutshabalalisa iiseli zomhlaza.
• Atezolizumab (Tecentriq) kunye ne-durvalumab
  (Imfinzi) vimba enye iprotein ebizwa ngokuba yi-PD-L1 kumphezulu weeseli zethumba kwaye
  iiseli zomzimba. Ukuthintela le protein kukwabangela ukuba amajoni omzimba aphendule
  umhlaza.

Ungayifumana nini i-immunotherapy?

Oogqirha basebenzisa iOpdivo, Keytruda, kunye neTecentriq njengonyango lodidi lwesibini. Unokufumana elinye lala machiza ukuba umhlaza wakho sele uqalile ukukhula kwakhona emva kwekhemotherapy okanye olunye unyango. I-Keytruda ikwabonelelwa njengonyango lodidi lokuqala lwenqanaba lokugqibela le-NSCLC, kunye nekhemotherapy.

U-Imfinzi ngowabantu abanesigaba 3 se-NSCLC abangakwaziyo ukwenza utyando, kodwa umhlaza wabo ungekho mbi emva kwekhemotherapy kunye nemitha. Kuyanceda ukunqanda umhlaza ekubeni ukhule ixesha elide kangangoko kunokwenzeka.

Uyifumana njani i-immunotherapy?

Amachiza e-Immunotherapy ahanjiswa njengokufakwa ngaphakathi kumthambo engalweni yakho. Uya kufumana la machiza kube kanye kwiiveki ezimbini ukuya kwezintathu.

Basebenza kakuhle kangakanani?

Abanye abantu baye bafumana iziphumo ezibi kumayeza e-immunotherapy. Unyango luye lwawanciphisa amathumba abo, kwaye luyekile umhlaza ekukhuleni iinyanga ezininzi.

Kodwa asinguye wonke umntu olwamkelayo olu nyango. Umhlaza usenokuma ithutyana, emva koko ubuye ubuye. Abaphandi bazama ukufunda ukuba yeyiphi na imihlaza ephendula ngcono kwi-immunotherapy, ke ngoko banokujolisa kolu nyango kubantu abaya kuthi bafumane olona ncedo kubo.

Zithini iziphumo ebezingalindelekanga?

Iziphumo eziqhelekileyo ezivela kumachiza e-immunotherapy zibandakanya:

• ukudinwa
• ukukhohlela
• isicaphucaphu
• ukurhawuzelela
• irhashalala
• ukungabi namdla wokutya
• ukuqhina
• urhudo
• intlungu edibeneyo

Iziphumo ebezingalindelekanga ezibi kakhulu zinqabile. Ngenxa yokuba la machiza enyusa ukuphendula komzimba, amajoni omzimba anokuqalisa ukuhlasela kwamanye amalungu anje ngemiphunga, izintso, okanye isibindi. Oku kunokuba kubi.

Yise kude

I-NSCLC ihlala ingafumaneki de kube kwinqanaba lokugqibela, isenza kube nzima ukunyanga ngotyando, i-chemotherapy, kunye ne-radiation. Unyango lwe-Immunotherapy luphucule unyango lwalo mhlaza.

Amachiza e-Checkpoint inhibitor anceda ukunciphisa ukukhula kwe-NSCLC esele isasazekile. La machiza awasebenzi kuye wonke umntu, kodwa anokunceda abanye abantu abane-NSCLC ekuhambeni kwexesha baye kuxolelo kwaye baphile ixesha elide.

Abaphandi bafunda amayeza amatsha e-immunotherapy kuvavanyo lweklinikhi. Ithemba kukuba amachiza amatsha okanye indibaniselwano entsha yala machiza nge-chemotherapy okanye i-radiation inokuphucula ukusinda nangakumbi.

Buza ugqirha wakho ukuba ichiza le-immunotherapy likulungele na. Fumanisa ukuba la mayeza angaluphucula njani unyango lwakho lomhlaza, kwaye ziziphi iziphumo ebezingalindelekanga ezinokubangela.